Vamil Divan
Stock Analyst at Guggenheim
(4.68)
# 184
Out of 4,969 analysts
230
Total ratings
66.05%
Success rate
17.73%
Average return
Main Sectors:
Stocks Rated by Vamil Divan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Buy | $216 → $227 | $211.86 | +7.15% | 27 | Aug 1, 2025 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $164 → $167 | $178.00 | -6.18% | 16 | Jul 17, 2025 | |
| PROK ProKidney | Maintains: Buy | $6 → $7 | $2.36 | +196.61% | 2 | Jul 14, 2025 | |
| JBIO Jade Biosciences | Upgrades: Buy | $14 | $7.55 | +85.43% | 1 | Jun 16, 2025 | |
| SVRA Savara | Maintains: Buy | $9 → $8 | $3.42 | +133.92% | 1 | May 28, 2025 | |
| AMGN Amgen | Assumes: Neutral | $288 | $283.85 | +1.46% | 1 | May 20, 2025 | |
| ANIP ANI Pharmaceuticals | Reiterates: Buy | $86 | $94.92 | -9.40% | 11 | May 12, 2025 | |
| VALN Valneva SE | Maintains: Buy | $15 → $14 | $8.81 | +58.91% | 1 | May 8, 2025 | |
| UNCY Unicycive Therapeutics | Initiates: Buy | $60 | $4.29 | +1,298.60% | 1 | Apr 21, 2025 | |
| MRK Merck & Co. | Reiterates: Buy | $115 | $84.18 | +36.61% | 14 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $47 | $19.61 | +139.67% | 8 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $23.90 | +29.71% | 1 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $2.38 | +320.17% | 3 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $24.79 | - | 22 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $59 → $61 | $22.97 | +165.62% | 5 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $101 | $143.50 | -29.62% | 6 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $15.76 | - | 5 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $26 | $1.47 | +1,668.71% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $9 | $0.84 | +971.30% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.58 | - | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $19 | $25.72 | -26.13% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $98 | $136.11 | -28.00% | 8 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $34 | $30.00 | +13.33% | 13 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $1.57 | +536.94% | 3 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $49 | $122.00 | -59.84% | 3 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $356 | $737.83 | -51.75% | 17 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $7.84 | -23.47% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $144 → $154 | $16.21 | +850.03% | 9 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $7.39 | +102.98% | 5 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $31.21 | - | 6 | Dec 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $18.76 | - | 13 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 | $5.62 | +166.90% | 4 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $58 → $61 | $47.50 | +28.42% | 8 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $103 | $2.43 | +4,138.68% | 3 | Jan 17, 2018 |
AbbVie
Aug 1, 2025
Maintains: Buy
Price Target: $216 → $227
Current: $211.86
Upside: +7.15%
Johnson & Johnson
Jul 17, 2025
Maintains: Neutral
Price Target: $164 → $167
Current: $178.00
Upside: -6.18%
ProKidney
Jul 14, 2025
Maintains: Buy
Price Target: $6 → $7
Current: $2.36
Upside: +196.61%
Jade Biosciences
Jun 16, 2025
Upgrades: Buy
Price Target: $14
Current: $7.55
Upside: +85.43%
Savara
May 28, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $3.42
Upside: +133.92%
Amgen
May 20, 2025
Assumes: Neutral
Price Target: $288
Current: $283.85
Upside: +1.46%
ANI Pharmaceuticals
May 12, 2025
Reiterates: Buy
Price Target: $86
Current: $94.92
Upside: -9.40%
Valneva SE
May 8, 2025
Maintains: Buy
Price Target: $15 → $14
Current: $8.81
Upside: +58.91%
Unicycive Therapeutics
Apr 21, 2025
Initiates: Buy
Price Target: $60
Current: $4.29
Upside: +1,298.60%
Merck & Co.
Apr 17, 2025
Reiterates: Buy
Price Target: $115
Current: $84.18
Upside: +36.61%
Apr 14, 2025
Reiterates: Buy
Price Target: $47
Current: $19.61
Upside: +139.67%
Mar 25, 2025
Initiates: Buy
Price Target: $31
Current: $23.90
Upside: +29.71%
Mar 20, 2025
Reiterates: Buy
Price Target: $10
Current: $2.38
Upside: +320.17%
Mar 18, 2025
Reiterates: Buy
Price Target: n/a
Current: $24.79
Upside: -
Feb 27, 2025
Maintains: Buy
Price Target: $59 → $61
Current: $22.97
Upside: +165.62%
Feb 25, 2025
Reiterates: Buy
Price Target: $101
Current: $143.50
Upside: -29.62%
Jan 17, 2025
Reiterates: Neutral
Price Target: n/a
Current: $15.76
Upside: -
Jun 15, 2023
Reiterates: Buy
Price Target: $26
Current: $1.47
Upside: +1,668.71%
Apr 3, 2023
Maintains: Buy
Price Target: $8 → $9
Current: $0.84
Upside: +971.30%
Mar 1, 2023
Initiates: Neutral
Price Target: n/a
Current: $2.58
Upside: -
Aug 10, 2022
Maintains: Neutral
Price Target: $27 → $19
Current: $25.72
Upside: -26.13%
Aug 8, 2022
Maintains: Neutral
Price Target: $95 → $98
Current: $136.11
Upside: -28.00%
Jul 28, 2022
Maintains: Buy
Price Target: $36 → $34
Current: $30.00
Upside: +13.33%
May 25, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $1.57
Upside: +536.94%
May 3, 2022
Maintains: Buy
Price Target: $51 → $49
Current: $122.00
Upside: -59.84%
May 2, 2022
Maintains: Buy
Price Target: $315 → $356
Current: $737.83
Upside: -51.75%
Mar 16, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $7.84
Upside: -23.47%
Mar 3, 2022
Maintains: Buy
Price Target: $144 → $154
Current: $16.21
Upside: +850.03%
May 6, 2021
Upgrades: Buy
Price Target: $15
Current: $7.39
Upside: +102.98%
Dec 13, 2019
Downgrades: Neutral
Price Target: n/a
Current: $31.21
Upside: -
Jul 10, 2019
Assumes: Neutral
Price Target: n/a
Current: $18.76
Upside: -
Aug 15, 2018
Assumes: Outperform
Price Target: $15
Current: $5.62
Upside: +166.90%
Jul 27, 2018
Maintains: Neutral
Price Target: $58 → $61
Current: $47.50
Upside: +28.42%
Jan 17, 2018
Initiates: Outperform
Price Target: $103
Current: $2.43
Upside: +4,138.68%